Harshabad Singh, Program Director Hepatobiliary and Pancreas Cancers at Mass General Brigham, shared on LinkedIn:
“To mark Pancreatic Cancer Awareness Month, yesterday we hosted the inaugural Mass General Brigham Cancer Institute Pancreatic Cancer Symposium.
More than 200 patients, caregivers, scientists, clinicians, and industry partners came together. The room was packed, and the momentum in the field and hope for a much better future for patients with this disease were palpable.

A few highlights from the day:
We opened with remarks from none other than David Ryan. He reminded us about miracles, pointing to the Colorado River, which day after day carved out the magnificent miracle of the Grand Canyon. The night before, at dinner with our keynote speaker Liz Jaffee, he told me about his early days building the GI oncology program at MGH, rounding on every post-op patient before a full clinic.
Day after day, Dave kept going, and our program today is proud to stand on his shoulders.
Liz Jaffee, who exemplifies this even more, then gave an inspiring keynote. She started on faculty at Hopkins in 1992, when no therapy was approved for pancreatic cancer. Seeing how far her work has carried pancreatic cancer immunology, now into vaccine and other interception trials, was inspiring.
David Ting showed how novel assays can move the needle with earlier readouts from interception and early detection trials.
Jen Wo then led an extremely powerful patient and caregiver session. We are grateful to everyone who shared their difficult journeys with us.
There wasn’t a dry eye in the room by the end.
Anna Berkenblit Pancreatic Cancer Action Network grateful for you being there, enhancing the program and for everything you do for patients with pancreatic cancer.

In the afternoon, Motaz Qadan walked us through the historical evolution of management of localized tumors, followed by
- novel KRAS inhibitors
- resistance
- combination strategies.
We highlighted MGB Cancer Institute innovation in the OR from Thomas Clancy, novel radiation technologies from Jen Wo, and multi-omic and spatial analysis from William Hwang.

The day had it all: science, novel technology, clinical trials, and life.
In short, the day was full of Medicine, the field I fell in love with decades ago, and yesterday reminded me why once again.
We could not have done this without my co-organizers Thomas Clancy, Jen Wo, Motaz Qadan, David Ting, and William Hwang.
Thank you to Liz for taking time out of a very busy schedule to deliver our keynote, and to our sponsors Astellas Pharma, Erasca, Inc., Guardant Health, Revolution Medicines, Tango Therapeutics, and Verastem Oncology.
And most importantly, thank you to our patients, who this is all about.”
You may also be interested in:
Thomas Clancy: MGB Cancer Institute to Host Its First Pancreatic Cancer Symposium
Vivek Subbiah: How Daraxonrasib Expands Treatment Access for Pancreatic Cancer
GeNeS1S Trial: Gemcitabine, Nab-Paclitaxel, and S-1 in Advanced Pancreatic Cancer
